TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-1943
Full Text
Open PDFAbstract
Available in full text
Date
September 12, 2018
Authors
Publisher
American Association for Cancer Research (AACR)